Harpoon Therapy Inc. (HARP)
(Delayed Data from NSDQ)
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HARP 10.59 -0.41(-3.73%)
Will HARP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HARP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HARP
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
HARP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Jan 9, 2024
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical